Zenas Biopharma (ZBIO) Competitors $8.92 +0.59 (+7.08%) As of 04/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock ZBIO vs. DVAX, MNKD, CLDX, INVA, NVAX, OPK, GERN, MYGN, RIGL, and VNDAShould you be buying Zenas Biopharma stock or one of its competitors? The main competitors of Zenas Biopharma include Dynavax Technologies (DVAX), MannKind (MNKD), Celldex Therapeutics (CLDX), Innoviva (INVA), Novavax (NVAX), OPKO Health (OPK), Geron (GERN), Myriad Genetics (MYGN), Rigel Pharmaceuticals (RIGL), and Vanda Pharmaceuticals (VNDA). These companies are all part of the "biotechnology" industry. Zenas Biopharma vs. Dynavax Technologies MannKind Celldex Therapeutics Innoviva Novavax OPKO Health Geron Myriad Genetics Rigel Pharmaceuticals Vanda Pharmaceuticals Zenas Biopharma (NASDAQ:ZBIO) and Dynavax Technologies (NASDAQ:DVAX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, community ranking, valuation, profitability, risk, earnings, institutional ownership and media sentiment. Which has higher earnings and valuation, ZBIO or DVAX? Dynavax Technologies has higher revenue and earnings than Zenas Biopharma. Zenas Biopharma is trading at a lower price-to-earnings ratio than Dynavax Technologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZenas Biopharma$5M74.57-$148.39M-$3.55-2.51Dynavax Technologies$277.25M4.61-$6.39M$0.1857.21 Does the media favor ZBIO or DVAX? In the previous week, Zenas Biopharma had 5 more articles in the media than Dynavax Technologies. MarketBeat recorded 15 mentions for Zenas Biopharma and 10 mentions for Dynavax Technologies. Dynavax Technologies' average media sentiment score of 0.04 beat Zenas Biopharma's score of 0.02 indicating that Dynavax Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zenas Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 14 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Dynavax Technologies 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 4 Very Negative mention(s) Neutral Do analysts rate ZBIO or DVAX? Zenas Biopharma presently has a consensus price target of $40.00, indicating a potential upside of 348.43%. Dynavax Technologies has a consensus price target of $20.50, indicating a potential upside of 99.09%. Given Zenas Biopharma's stronger consensus rating and higher possible upside, equities analysts clearly believe Zenas Biopharma is more favorable than Dynavax Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zenas Biopharma 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Dynavax Technologies 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Do insiders & institutionals have more ownership in ZBIO or DVAX? 97.0% of Dynavax Technologies shares are owned by institutional investors. 3.0% of Dynavax Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is ZBIO or DVAX more profitable? Dynavax Technologies has a net margin of 9.85% compared to Zenas Biopharma's net margin of 0.00%. Dynavax Technologies' return on equity of 4.22% beat Zenas Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Zenas BiopharmaN/A N/A N/A Dynavax Technologies 9.85%4.22%2.67% Does the MarketBeat Community favor ZBIO or DVAX? Dynavax Technologies received 474 more outperform votes than Zenas Biopharma when rated by MarketBeat users. However, 100.00% of users gave Zenas Biopharma an outperform vote while only 65.84% of users gave Dynavax Technologies an outperform vote. CompanyUnderperformOutperformZenas BiopharmaOutperform Votes2100.00% Underperform VotesNo VotesDynavax TechnologiesOutperform Votes47665.84% Underperform Votes24734.16% SummaryDynavax Technologies beats Zenas Biopharma on 11 of the 16 factors compared between the two stocks. Get Zenas Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ZBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZBIO vs. The Competition Export to ExcelMetricZenas BiopharmaBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket Cap$372.85M$121.00M$5.30B$7.34BDividend YieldN/A3.75%5.45%4.30%P/E Ratio-2.513.0521.8617.80Price / Sales74.574,230.63380.6797.70Price / CashN/A13.1938.2634.64Price / BookN/A34.276.453.98Net Income-$148.39M-$91.73M$3.22B$247.81M1 Month Performance8.12%-5.11%-9.74%-7.85%1 Year PerformanceN/A83.94%11.49%1.59% Zenas Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZBIOZenas BiopharmaN/A$8.92+7.1%$40.00+348.4%N/A$372.85M$5M-2.51N/ANews CoverageGap DownDVAXDynavax Technologies4.182 of 5 stars$11.34-0.9%$21.50+89.6%-9.2%$1.41B$277.25M63.14350Analyst ForecastNews CoverageMNKDMannKind2.142 of 5 stars$4.63-0.1%$9.56+106.8%+11.3%$1.41B$285.50M66.07400CLDXCelldex Therapeutics2.675 of 5 stars$18.21+2.4%$54.33+198.3%-52.5%$1.21B$7.02M-7.09150Positive NewsINVAInnoviva4.3446 of 5 stars$18.13+0.8%$55.00+203.4%+24.4%$1.14B$358.71M26.26100Positive NewsNVAXNovavax3.5829 of 5 stars$6.23-2.8%$18.00+188.9%+54.2%$1.00B$682.16M-2.761,990Options VolumeAnalyst RevisionOPKOPKO Health4.1082 of 5 stars$1.45+1.8%$2.75+90.3%+15.4%$970.39M$713.14M-7.613,930Options VolumeGERNGeron3.7731 of 5 stars$1.26-4.9%$5.75+358.2%-66.0%$805.68M$76.99M-3.9570Short Interest ↑MYGNMyriad Genetics3.7623 of 5 stars$8.09+0.1%$20.89+158.4%-58.7%$739.15M$837.60M-6.232,700Analyst ForecastNews CoverageRIGLRigel Pharmaceuticals2.8828 of 5 stars$17.39+1.1%$36.80+111.6%+60.5%$311.53M$179.28M124.58160News CoveragePositive NewsVNDAVanda Pharmaceuticals4.1647 of 5 stars$4.36-0.1%$16.50+278.9%-12.9%$254.55M$198.77M-13.64290News Coverage Related Companies and Tools Related Companies DVAX Alternatives MNKD Alternatives CLDX Alternatives INVA Alternatives NVAX Alternatives OPK Alternatives GERN Alternatives MYGN Alternatives RIGL Alternatives VNDA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZBIO) was last updated on 4/19/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zenas Biopharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Zenas Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ZBIO Stock Free ZBIO Stock Alerts